Determination of Anti‐Parkinson Drug Pramipexole Using a Label‐free Biosensor and Evaluation of its Interaction with ds‐DNA

Garkani-Nejad, Zahra

doi:10.1002/elan.202100551

Cited by 3 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(2) The incidence of adverse reactions was compared between the two groups. (3) The Unified Parkinson's Disease Rating Scale (UPDRS) [5][6][7] was used to evaluate the symptoms of the disease. The scale comprised a total of 42 items, encompassing assessments of activities of daily living (UPDRS II), exercise capacity (UPDRS III), and complications (UPDRS IV), with 4, 27, and 11 items, respectively.…”

Section: Evaluation Of Efficacy and Evaluation Indexmentioning

confidence: 99%

Effect Evaluation of Madopar Combined with Pramipexole in the Treatment of Parkinson’s Patients

Liu,

Wang,

Tan

2023

CNR

View full text Add to dashboard Cite

Objective: To analyze the clinical efficacy of Madopar combined with pramipexole in the treatment of Parkinson’s disease. Methods: This study was conducted from January 2021 to January 2023. This study involved 80 patients who were divided into two groups using a computerized randomization. The control group received pramipexole and the experimental group received both madopar and pramipexole. The treatment outcomes of these two groups were compared and analyzed. Results: The efficacy of the treatment received in the experimental group was 95.00%, which was higher than that of the control group (77.50%), whereas the total adverse reaction rate of the experimental group was 12.50%, which was lower than that of the control group, 35.00%; the difference was significant (P < 0.05). There was no difference in the levels of tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), C-reactive protein (CRP), miR-124, miR-137, and Unified Parkinson’s Disease Rating Scale (UPDRS) total score (UPDRS Ⅱ, UPDRS Ⅲ, and UPDRS Ⅳ scores) between the control group and the experimental group (P > 0.05). After treatment, these indicators were significantly improved in the experimental group compared to the control group. Conclusion: Madopar combined with pramipexole in the treatment of Parkinson’s is both effective and safe. It delays the progression of the disease and has broad application prospects.

show abstract

Section: Evaluation Of Efficacy and Evaluation Indexmentioning

confidence: 99%